ITCI News and Press, Intra-Cellular Therapies Inc. From 08/09/22

Intra-Cellular Therapies, Inc. (ITCI) Q2 2022 Earnings Conference Call August 09, 2022, 08:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relations Sharon Mates - Chairman and Chief Executive Officer Mark Neuman...

Intra-Cellular Therapies press release ( NASDAQ: ITCI ): Q2 GAAP EPS of -$0.92 misses by $0.15 . Revenue of $55.6M (+177.3% Y/Y) beats by $6.98M . Cash, cash equivalents, restricted cash and investment securities totaled $679.2M at June 30, 2022, compared to $4...

Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase CAPLYTA net product revenues for the second quarter 2022 were $55.1 million, representing a 190% increase over the sa...

Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.76 (+10.6% Y/Y) and the consensus Revenue Estimate is $48.62M (+142.5% Y/Y). Over the last 1 year, ITCI ...

Axsome Therapeutics encountered some regulatory setbacks relating to its lead medicine AXS05 for major depressive disorder. Axsome recently posted more positive data on AXS05 for such depression. More importantly, the firm indicated its upcoming labeling discussion for AXS05 with the ...

Biopharmaceutical companies Athira Pharma ( ATHA ) and BioXcel Therapeutics ( BTAI ) have outperformed the gains in the biotech space on Thursday after Mizuho launched their coverage on small and mid-cap names focused on the central nervous system (CNS). Despite being a high...

Intra-Cellular's atypical antipsychotic CAPLYTA has all the makings of a blockbuster. Now in its initial bipolar launch phase, CAPLYTA is succeeding on all three key leading indicators. Intra-Cellular's financial position is a work in process. For further details see: In...

Intra-Cellular Therapies (NASDAQ:ITCI) closed higher on Tuesday after UBS launched its coverage with a Buy rating and a $75 per share target noting that the commercial-stage pharma company is set to benefit from the launch of its only commercial product Caplyta for bipolar depression. In Dece...

NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the 2022 International So...

Wasatch Global Investors is a comprehensive small-cap equity manager singularly focused on delivering superior risk-adjusted returns for our clients. If we don’t perceive macro events as impacting long-term company fundamentals, our response is to stay the course. During th...